00874 BAIYUNSHAN PHWatchlist
BAIYUNSHAN PH News
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) stock is up by a considerable 7.5% over the past week. Given that stock prices are usually aligned with a company's financial performance in t
Everbright Securities: Four Advantages of Accelerating Transformation and Upgrading of the Traditional Chinese Medicine Industry, Value Revaluation
The Zhitong Finance app learned that Everbright Securities published a research report saying that traditional Chinese medicine has rich clinical positioning and broad market space. Under medical reform policies and industry standards, quality, safety, and efficacy have continued to improve.
Changes in Hong Kong stocks | Modern Chinese Medicine Group (01643) rose by more than 4%, leading the Chinese medicine concept, favorable policies, and continued release of sectors with allocation value
Some traditional Chinese medicine concept stocks rose. As of press release, Modern Chinese Medicine Group (01643) rose 4.29% to HK$0.365; Zhongzhi Pharmaceutical (03737) rose 2.84% to HK$1.45; and Tong Ren Tang Technology (01666) rose 2.08% to HK$6.39.
Changes in Hong Kong stocks | Tong Ren Tang Sinopharm (03613) rose nearly 6%, leading the traditional Chinese medicine concept, the traditional Chinese medicine development policy is expected to continue to be introduced, quarterly fluctuations will not c
Traditional Chinese medicine concept stocks generally rose today. As of press release, Kangchen Pharmaceutical (01681) rose 3.67% to HK$4.8; Tong Ren Tang Sinopharm (03613) rose 3.39% to HK$12.82; Baiyunshan (00874) rose 2.9% to HK$21.3; and Chinese Traditional Chinese Medicine (00570) rose 1.37% to HK$3.69.
Guangzhou Pharmaceutical Group, the controlling shareholder of Baiyunshan (00874), received the Supreme Court's notice of acceptance of the appeal in the second instance of the retrial phase of the “Wang Laoji” trademark legal dispute lawsuit
Baiyunshan (00874) announced that Guangzhou Pharmaceutical Group Co., Ltd., the controlling shareholder of the company (hereinafter referred to as “Guangzhou Pharmaceutical Group” or...
Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Key Insights The projected fair value for Guangzhou Baiyunshan Pharmaceutical Holdings is HK$25.35 based on 2 Stage Free Cash Flow to Equity Current share price of HK$20.45 suggests Guangzhou Baiyun
Guangzhou Pharma Expands Scope of Drug Production License
Guangzhou Pharmaceutical Holdings (SHA:600332, HKG:0874) has obtained approval to expand the scope of its drug production license in China's Guangdong province. The company now holds a license to prod
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
CITIC Construction Investment: Positive year-on-year growth in pharmaceutical revenue in the first three quarters favors prescription drugs, traditional Chinese medicine, etc.
The overall sector's revenue in the first three quarters of 2023 achieved positive year-on-year growth, and the growth rate declined in the third quarter. The growth rate slowed mainly due to increased compliance requirements, but the downturn was not overshadowed, and immediate demand and innovation drove the industry's Q3 revenue to continue to grow.
As Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Lifts 3.2% This Past Week, Investors May Now Be Noticing the Company's Five-year Earnings Growth
The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term Guangzhou Baiyunshan Pha
Guangzhou Baiyunshan Pharmaceutical's Profit Up 11% in Q3
Guangzhou Baiyunshan Pharmaceutical Holdings (SHA:600332, HKG:0874) recorded a 10.81% year-over-year rise in attributable profit for the three months ended Sept. 30 to 980 million yuan. Diluted earnin
BAIYUNSHAN PH: 2023 THIRD QUARTERLY REPORT
Accounts receivable from Baiyun Mountain (00874.HK) subsidiary sale
Gelonghui, October 30, Baiyunshan (00874.HK) announced that on October 30, 2023, Guangzhou Pharmaceutical (a non-wholly owned subsidiary of the company established in China, where the company owns 90.92% of the shares) and Xing Securities Asset Management signed a “New Basic Asset Delivery Confirmation Letter” in accordance with the underlying asset transaction agreement (Phase III), confirming the sale of the third additional underlying asset to XSE Asset Management and received a purchase price of about RMB 688 million.
Baiyun Mountain: Cefuroxime sodium for injection (0.5g) has passed a consistent evaluation of the quality and efficacy of generic drugs
Baiyunshan (00874) announced that recently, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as “Tianxin Pharmaceutical”), a holding subsidiary of the company, received the “Drug Supplement Application Approval Notice” (Notice Number: 2023B05073) approved and issued by the State Drug Administration. Cefuroxime sodium for injection (0.5g) has passed a consistent evaluation of the quality and efficacy of generic drugs. Cefuroxime sodium for injection is Tianxin Pharmaceutical's first domestic generic drug and was marketed in 1994. Tianxin Pharmaceutical submitted cefuroxime sodium for injection to the State Drug Administration on February 23, 2023 (0
Private Companies Account for 46% of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Ownership, While Individual Investors Account for 35%
Key Insights Guangzhou Baiyunshan Pharmaceutical Holdings' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 53% of the bu
Baiyun Mountain (00874.HK) will hold a board meeting on October 30 to approve the first three quarter results
Glonghui, October 16, 丨 Baiyunshan (00874.HK) announced that the board of directors of the company hereby announces that a board meeting will be held on October 30, 2023 to review and approve the unaudited financial results of the company and its subsidiaries for the nine months ended September 30, 2023 and handle other matters (if any).
Here's Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investment
CITIC Construction Investment: Innovative pharmaceutical companies are still optimistic about segments such as prescription drugs and medical devices on the high-value investment track
The Zhitong Finance App learned that CITIC Construction Investment released a research report stating that last week it focused on reviewing the mid-term business conditions of pharmaceutical companies and innovative pharmaceutical companies.
Here's What To Make Of Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Decelerating Rates Of Return
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expand
Baiyunshan Pharmaceutical Reports Increase in H1 Attributable Profit
Guangzhou Baiyunshan Pharmaceutical Holdings' (SHA:600332, HKG:0874) attributable profit increased to 2.81 billion yuan, or 1.729 yuan per share, in the first half, from 2.59 billion yuan, or 1.593 yu